pegasys rbv solution
hoffmann-la roche limited - peginterferon alfa-2a; ribavirin - solution - 180mcg; 200mg - peginterferon alfa-2a 180mcg; ribavirin 200mg - interferons
pegasys solution
pharmaand gmbh - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons
pegasys solution
hoffmann-la roche limited - peginterferon alfa-2a - solution - 180mcg - peginterferon alfa-2a 180mcg - interferons
pegasys rbv
roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg; ; - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease
pegasys rbv
roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg; ; - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease
peg-intron clearclick injector
merck sharp & dohme (new zealand) limited - peginterferon alfa-2b 100ug - injection with diluent - 100 mcg - active: peginterferon alfa-2b 100ug excipient: dibasic sodium phosphate monobasic sodium phosphate dihydrate polysorbate 80 sucrose water for injection
dalfampridine tablet, film coated, extended release
actavis pharma, inc. - dalfampridine (unii: bh3b64okl9) (dalfampridine - unii:bh3b64okl9) - dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (ms). this was demonstrated by an increase in walking speed [see clinical studies (14)]. the use of dalfampridine is contraindicated in the following conditions: - history of seizure [see warnings and precautions (5.1)] - moderate or severe renal impairment (crcl ≤50 ml/min) [see warnings and precautions (5.2)] - history of hypersensitivity to dalfampridine or 4-aminopyridine; reactions have included anaphylaxis [see warnings and precautions (5.4)] risk summary there are no adequate data on the developmental risk associated with use of dalfampridine in pregnant women. administration of dalfampridine to animals during pregnancy and lactation resulted in decreased offspring viability and growth at clinically relevant doses [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% an
rebetron ready to use solution (albumin(human)free) (6000000 iu/ml and 200mg capsules) kit
schering-plough canada inc - ribavirin; interferon alfa-2b - kit - 200mg; 6000000unit - ribavirin 200mg; interferon alfa-2b 6000000unit - interferons
rebetron solution (albumin (human) free) (18 miu multi-dose pen / 200mg capsules) kit
schering-plough canada inc - ribavirin; interferon alfa-2b - kit - 200mg; 15000000unit - ribavirin 200mg; interferon alfa-2b 15000000unit - interferons
intron a inj 3000000unit/vial liquid
avondale (brinny) chemical company - interferon alfa-2b - liquid - 3000000unit - interferon alfa-2b 3000000unit - antineoplastic agents